Andres Nisimblat, MD
Family Medicine · Corpus Christi, TXNPI 1467469205
Payments from drug & device makers
Across 640 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Amgen$867
- GSK$807
- Pfizer$609
- Kowa Pharmaceuticals America, Inc.$575
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,723100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 144 | $1,974 |
| Lilly USA, LLC | 113 | $1,333 |
| Amgen | 58 | $867 |
| GSK | 51 | $807 |
| Pfizer | 38 | $609 |
| Kowa Pharmaceuticals America, Inc. | 36 | $575 |
| Merck | 29 | $510 |
| Amarin Pharma, Inc. | 24 | $469 |
| Dexcom, Inc. | 25 | $412 |
| AstraZeneca | 19 | $322 |
| AbbVie | 14 | $242 |
| Sanofi Pasteur Inc. | 13 | $225 |
| Bayer | 11 | $214 |
| Esperion Therapeutics, Inc. | 8 | $174 |
| Exact Sciences | 9 | $162 |
| Boehringer Ingelheim | 6 | $111 |
| Shield Therapeutics Inc | 6 | $89 |
| Novartis | 4 | $89 |
| Phathom Pharmaceuticals, Inc. | 3 | $55 |
| Radius Health, Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Arbor Pharmaceuticals, Inc. | 2 | $41 |
| Corcept Therapeutics | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| IBSA Pharma Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Vistapharm, Inc. | 2 | $23 |
| Phadia US Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
How this compares
$9,750 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 252 | $252,541 |
| EliquisApixaban | 126 | $120,344 |
| JardianceEmpagliflozin | 94 | $82,108 |
| MounjaroTirzepatide | 49 | $60,209 |
| JulucaDolutegravir/Rilpivirine | 12 | $48,051 |
| TrulicityDulaglutide | 33 | $43,720 |
| FarxigaDapagliflozin Propanediol | 49 | $39,353 |
| JanuviaSitagliptin Phosphate | 19 | $20,746 |
| XareltoRivaroxaban | 16 | $19,633 |
| RybelsusSemaglutide | 16 | $17,746 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $17,389 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $16,713 |
| KerendiaFinerenone | 15 | $10,513 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $5,707 |
| Levothyroxine Sodium | 438 | $5,693 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,974 | $270,287268 claims |
| PfizerEliquis | $609 | $120,344126 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,333 | $103,92982 claims |
| Boehringer IngelheimJardiance | $111 | $82,10894 claims |
| AstraZenecaFarxiga | $322 | $39,35349 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $807 | $21,79737 claims |
| MerckJanuvia | $510 | $20,74619 claims |
| BayerKerendia | $214 | $10,51315 claims |
| AbbVieSynthroid | $242 | $2,92867 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Corpus Christi
- Michael WinnieCorpus Christi$3.9M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.